New mRNA treatment for pre-eclampsia
mRNA lipid nanoparticles for pre-eclampsia
This project aims to create a new mRNA treatment delivered by tiny particles to help manage pre-eclampsia during pregnancy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11166526 on NIH RePORTER |
What this research studies
Pre-eclampsia is a serious pregnancy condition causing high blood pressure and can harm both mother and baby. Current treatments only manage symptoms, and the only cure is early delivery, which can be risky for the baby. This work focuses on developing a new kind of medicine using mRNA, delivered by special tiny particles called lipid nanoparticles. These particles are designed to specifically target the placenta, the organ that connects mother and baby. The hope is that this new approach can help relax blood vessels in the placenta, reduce the mother's high blood pressure, and improve the baby's health.
Who could benefit from this research
Good fit: Pregnant individuals diagnosed with pre-eclampsia after 20 weeks of gestation, who currently lack effective treatments to slow disease progression, would be the target beneficiaries.
Not a fit: Patients without pre-eclampsia or those whose condition is already managed by existing symptomatic treatments may not directly benefit from this specific therapeutic approach.
Why it matters
Potential benefit: If successful, this new treatment could slow the progression of pre-eclampsia, reduce maternal high blood pressure, and improve fetal outcomes without requiring early delivery.
How similar studies have performed: While current treatments manage symptoms, there are no existing drugs to slow the progression of pre-eclampsia, making this a novel and much-needed therapeutic strategy.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Mitchell, Michael J — University of Pennsylvania
- Study coordinator: Mitchell, Michael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.